The U.S. Food & Drug Administration (FDA) regulator gave more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.


50


Reuters

13 Related Articles, between 2018-11-05 and 2018-11-02